news
Empagliflozin trial halted after successful outcome in chronic kidney disease
An early halt has been called to a major kidney drug trial following positive results for patients with chronic kidney disease (CKD).
List view / Grid view
Clinical Trials
news
Potential for a new one-and-done COVID-19 treatment
Investigational drug Lambda reduced risk of COVID-19-related death in one of the largest studies of its kind to date.
news
Is Aduhelm® of benefit to Alzheimer’s patients long-term?
New data shows that patients taking Aduhelm® (aducanumab-avwa) had significant reductions in tau and amyloid beta after nearly 2.5 years.
news
AbbVie’s preventative migraine treatment atogepant (Qulipta™) shows promise
AbbVie releases promising results from its Phase III trial of atogepant (Qulipta™) for preventative treatment of chronic migraine.
news
Roche’s Evrysdi® shows long-term efficacy in spinal muscular atrophy
New data demonstrates the long-term safety and efficacy of Evrysdi® (risdiplam) in a broad population of people with spinal muscular atrophy (SMA).
news
First participants dosed with pan-antiviral nasal spray in Phase IIa trial
The Phase IIa influenza-challenge study will enrol 123 healthy adults and support the development of INNA-051 as a pan-antiviral nasal spray.
news
Positive Phase I results for Pipe-307 treatment for MS
Pipe-307 demonstrated linear pharmacokinetic (PK) data consistent with pre-clinical modelling and was generally well tolerated at all doses in 70 healthy adult volunteers.
news
mRNA vaccine candidates for HIV enter Phase I trial
Will mRNA vaccines one day protect against HIV? Three investigational mRNA vaccines, all designed to combat HIV, have entered Phase I testing.
news
Could AAT be the answer to COVID-19 ARDS?
Clinical study finds alpha-1 antitryspin (AAT) reduces pro-inflammatory IL-6 and therefore may benefit COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS).
news
Pharmacovigilance Risk Assessment Committee (PRAC) meeting highlights, March 2022
EMA’s pharmacovigilance committee recommends product information updates for two COVID-19 vaccines - Janssen COVID-19 Vaccine and Moderna’s Spikevax.
news
Novel radioligand therapy shows promise in metastatic prostate cancer
New data suggests 225Ac-PSMA-617 radioligand therapy could improve overall survival in metastatic prostate cancer patients.
news
Efanesoctocog alfa prevents bleeding episodes in haemophilia A patients
Efanesoctocog alfa significantly and meaningfully reduces annualised bleeding rates in haemophilia A patients, according to new Phase III data.
news
Kisqali increases overall survival in advanced breast cancer patients by 12 months
Kisqali plus letrozole achieved a median overall survival (OS) of over five years (63.9 months), with OS benefit increasing over time, according to newly published data.
news
Trodelvy® improves breast cancer progression-free survival, finds study
Trodelvy® (sacituzumab govitecan-hziy) was found to significantly reduce the risk of disease progression or death in certain breast cancer patients.
news
Phase III study shows safety of fezolinetant as non-hormonal treatment of VMS
The safety and efficacy of fezolinetant is being evaluated in the Phase III trial of over 1,800 women seeking relief from severe vasomotor symptoms associated with menopause (VMS).
